Author

C. Wu

Institution: University of California, San Francisco

Observed institution: University of California, San Francisco

OpenAlex ID: A5126267157

Abstract PD10-02: I- SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant vepdegestrant monotherapy or in combination with letrozole or abemaciclib in molecularly selected patients with stage 2/3 HR+ HER2-negative breast cancer (BC)

2026 · J. Chien, R. M. Mukhtar, et al. · Clinical Cancer Research · 1

PS4-05-28: Impact of Neoadjuvant Endocrine Therapy on MammaPrint Index in Hormone Receptor-Positive, HER2-Negative MammaPrint Low Risk Early-Stage Breast Cancer

2026 · S. Jacob, C. Wu, et al. · Clinical Cancer Research

Abstract PS4-02-01: Differential early response to neoadjuvant endocrine therapy in lobular versus non-lobular breast cancer on the Endocrine Optimization Pilot (EOP) of the I-SPY2 Trial

2026 · R. Mukhtar, P. Norwood, et al. · Clinical Cancer Research

Works count: 3

Citation count: 1

H-index: 1

I10-index: